---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-110241"
form_type: "8-K"
ticker: "CLYD"
cik: "0002094256"
company_name: "BEACON TOPCO, INC."
filed_at: "2026-09-24T13:19:17+00:00"
generated_at: "2026-09-24T13:20:11.217091+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Balomenib Phase 1b shows durable HbA1c improvement; Merger closing extended to Oct 31

## Summary
- Merger closing date for Clywedog acquisition amended to Oct 31, 2026 (or earlier mutual agreement); End Date also Oct 31, 2026.
- Phase 1b: placebo-adjusted HbA1c -0.77% at Week 12 (p<0.01) and -0.70% at Week 16 (p<0.05) after 3-week dosing.
- OGTT: placebo-adjusted reductions in total glucose AUC 203 mmol·min/L (p=0.019), peak glucose 2.03 mmol/L (p=0.013), 2-hr glucose 2.46 mmol/L (p=0.010).
- FPG reduced by 1.29 mmol/L (23 mg/dL) at Week 12 (p<0.05); no drug-related serious/severe AEs or discontinuations.
- Phase 2a with 12-week treatment course expected to initiate in Q4 2026.

## SEC filing metadata
- accession: 0001104659-26-110241
- form_type: 8-K
- ticker: CLYD
- cik: 0002094256
- company_name: BEACON TOPCO, INC.
- filed_at: 2026-09-24T13:19:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2094256/000110465926110241/0001104659-26-110241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2094256/000110465926110241/tm2625953d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-110241
- JSON: https://secwatch.observer/filing/0001104659-26-110241.json
- Plain text: https://secwatch.observer/filing/0001104659-26-110241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.